This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rao, K. V. N. Articles by McCormick, D. L. Search for Related Content PubMed PubMed Citation Articles by Rao, K. V. N. Articles by McCormick, D. L.

Chemoprevention of Rat Prostate Carcinogenesis by Early and Delayed Administration of Dehydroepiandrosterone¹

Experimental Toxicology and Carcinogenesis Division, IIT Research Institute, Chicago, Illinois 60616 [K. V. N. R., W. D. J., D. L. M.]; Departments of Environmental Medicine and Urology, New York University School of Medicine, New York, New York 10016 [M. C. B.]; and Chemoprevention Branch, National Cancer Institute, Bethesda, Maryland 20892 [R. A. L., V. E. S., G. J. K.]

Two in vivo bioassays were conducted to evaluate the efficacy of dehydroepiandrosterone (DHEA) as an inhibitor of prostate carcinogenesis in rats. Prostate adenocarcinomas were induced in male Wistar-Unilever rats by a sequential regimen of cyproterone acetate and testosterone propionate, followed by a single i.v. injection of N-methyl-N-nitrosourea (MNU) and chronic androgen stimulation. In the first experiment, DHEA (1000 or 2000 mg/kg diet) was administered continuously to rats beginning 1 week before MNU exposure. In the second experiment, continuous administration of DHEA (2000 mg/kg diet) was begun either 1 week before, 20 weeks after, or 40 weeks after MNU exposure. Controls received basal diet without added DHEA. Studies were terminated at 13 months after MNU administration, and prostate cancer incidence was determined by histopathological evaluation of step sections of accessory sex glands. In the first study, continuous dietary administration of DHEA beginning 1 week before MNU resulted in a dose-related inhibition of prostate cancer induction. In the second experiment, comparable reductions in prostate cancer incidence were observed in groups exposed to DHEA beginning 1 week before, 20 weeks after, and 40 weeks after carcinogen exposure. These data demonstrate that nontoxic doses of DHEA confer significant protection against prostate carcinogenesis in rats. The efficacy of delayed administration of DHEA suggests that the compound confers protection against later stages of prostate cancer induction and can suppress the progression of existing preneoplastic lesions to invasive disease.

This article has been cited by other articles:

				N. Homma, T. Nagaoka, V. Karoor, M. Imamura, L. Taraseviciene-Stewart, L. A. Walker, K. A. Fagan, I. F. McMurtry, and M. Oka Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L71 - L78. [Abstract] [Full Text] [PDF]

				V. V. Mossine, P. Chopra, and T. P. Mawhinney Interaction of Tomato Lycopene and Ketosamine against Rat Prostate Tumorigenesis Cancer Res., June 1, 2008; 68(11): 4384 - 4391. [Abstract] [Full Text] [PDF]

				B. A. Narayanan, B. S. Reddy, M. C. Bosland, D. Nargi, L. Horton, C. Randolph, and N. K. Narayanan Exisulind in Combination with Celecoxib Modulates Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Cyclin D1 against Prostate Carcinogenesis: In vivo Evidence Clin. Cancer Res., October 1, 2007; 13(19): 5965 - 5973. [Abstract] [Full Text] [PDF]

				D. L. McCormick, W. D. Johnson, N. M. Kozub, K.V.N. Rao, R. A. Lubet, V. E. Steele, and M. C. Bosland Chemoprevention of rat prostate carcinogenesis by dietary 16{alpha}-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone Carcinogenesis, February 1, 2007; 28(2): 398 - 403. [Abstract] [Full Text] [PDF]

				J. T. Arnold, H. Le, K. K. McFann, and M. R. Blackman Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E573 - E584. [Abstract] [Full Text] [PDF]

				T. W.-M. Boileau, Z. Liao, S. Kim, S. Lemeshow, J. W. Erdman Jr., and S. K. Clinton Prostate Carcinogenesis in N-methyl-N-nitrosourea (NMU)-Testosterone-Treated Rats Fed Tomato Powder, Lycopene, or Energy-Restricted Diets J Natl Cancer Inst, November 5, 2003; 95(21): 1578 - 1586. [Abstract] [Full Text] [PDF]

				B. A. Narayanan, M. S. Condon, M. C. Bosland, N. K. Narayanan, and B. S. Reddy Suppression of N-Methyl-N-nitrosourea/Testosterone-induced Rat Prostate Cancer Growth by Celecoxib: Effects on Cyclooxygenase-2, Cell Cycle Regulation, and Apoptosis Mechanism(s) Clin. Cancer Res., August 1, 2003; 9(9): 3503 - 3513. [Abstract] [Full Text] [PDF]

				J. E. Green, M.-A. Shibata, E. Shibata, R. C. Moon, M. R. Anver, G. Kelloff, and R. Lubet 2-Difluoromethylornithine and Dehydroepiandrosterone Inhibit Mammary Tumor Progression but not Mammary or Prostate Tumor Initiation in C3(1)/SV40 T/t-antigen Transgenic Mice Cancer Res., October 1, 2001; 61(20): 7449 - 7455. [Abstract] [Full Text] [PDF]

				Y. C. Ou, R. B. Conolly, R. S. Thomas, Y. Xu, M. E. Andersen, L. S. Chubb, H. C. Pitot, and R. S. H. Yang A Clonal Growth Model: Time-course Simulations of Liver Foci Growth following Penta- or Hexachlorobenzene Treatment in a Medium-term Bioassay Cancer Res., March 1, 2001; 61(5): 1879 - 1889. [Abstract] [Full Text]

				T. W. M. Boileau, S. K. Clinton, and J. W. Erdman Jr. Tissue Lycopene Concentrations and Isomer Patterns Are Affected by Androgen Status and Dietary Lycopene Concentration in Male F344 Rats J. Nutr., June 1, 2000; 130(6): 1613 - 1618. [Abstract] [Full Text]